이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

전이성 거세 저항성 전립선암 환자 치료에서 도세탁셀을 병용하거나 병용하지 않는 M6620 및 카보플라틴

2026년 11월 11일 업데이트: National Cancer Institute (NCI)

전이성 거세 저항성 전립선암에서 M6620(VX-970, Berzosertib)과 카보플라틴 병용 요법의 2상 연구와 카보플라틴 병용 도세탁셀의 비교

This phase II trial studies how well berzosertib (M6620) and carboplatin with or without docetaxel works in treating patients with castration-resistant prostate cancer that has spread to other places in the body (metastatic). M6620 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as carboplatin and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving M6620, carboplatin and docetaxel may work better in treating patients with metastatic castration-resistant prostate cancer compared to carboplatin and docetaxel alone.

연구 개요

상세 설명

PRIMARY OBJECTIVE:

I. To assess the difference in response rate (either achievement of prostate specific antigen [PSA] reduction of greater than 50% or radiographic response by Response Evaluation Criteria in Solid Tumors [RECIST] 1.1) of the combination of berzosertib (M6620) (VX-970, berzosertib) and carboplatin as compared to the combination of docetaxel and carboplatin.

SECONDARY OBJECTIVES:

I. To assess the difference in time to PSA progression by Prostate Cancer Working Group (PCWG)2 criteria of the combination of M6620 (VX-970, berzosertib) and carboplatin as compared to the combination of docetaxel and carboplatin.

II. To describe radiographic progression-free survival and progression-free survival by PCWG3 criteria in both arms of the study.

III. Assess the relationship with homologous recombination deficiency (HRD) detected from baseline tumor biopsy with response to the combination of M6620 (VX-970, berzosertib) and carboplatin and the combination of docetaxel and carboplatin.

IV. To describe the safety and adverse events from the combination of M6620 (VX-970, berzosertib) + carboplatin as well the combination of docetaxel + carboplatin.

EXPLORATORY OBJECTIVES:

I. Comparison of overall survival in the two arms of the study. II. Explore response rate, time to PSA progression, radiographic progression-free survival, and progression-free survival by PCWG3 criteria in patients who initially receive docetaxel + carboplatin after crossover to M6620 + carboplatin.

III. To assess the relationship with homologous recombination deficiency (HRD) detected from baseline circulating free deoxyribonucleic acid (DNA) (cfDNA) with response to the combination of M6620 and carboplatin and the combination of docetaxel and carboplatin, and describe alterations seen in cfDNA (and optional tumor biopsy) at end of study.

OUTLINE: Patients are randomized to 1 of 2 groups.

ARM A (docetaxel, carboplatin): Patients receive docetaxel intravenously (IV) over 60 minutes and carboplatin IV over 30 minutes on day 1 or carboplatin alone on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients have PSA progression or radiographic progression may crossover to Arm B.

ARM B (carboplatin, berzosertib): Patients receive carboplatin IV over 30 minutes on day 1 and berzosertib IV over 60-90 minutes on days 2 and 9. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up between 30-42 days.

연구 유형

중재적

등록 (실제)

73

단계

  • 2 단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

    • California
      • Duarte, California, 미국, 91010
        • City of Hope Comprehensive Cancer Center
      • La Jolla, California, 미국, 92093
        • UC San Diego Moores Cancer Center
      • Sacramento, California, 미국, 95817
        • University of California Davis Comprehensive Cancer Center
    • Colorado
      • Aurora, Colorado, 미국, 80045
        • UCHealth University of Colorado Hospital
    • Connecticut
      • Derby, Connecticut, 미국, 06418
        • Smilow Cancer Hospital-Derby Care Center
      • Fairfield, Connecticut, 미국, 06824
        • Smilow Cancer Hospital Care Center-Fairfield
      • Guilford, Connecticut, 미국, 06437
        • Smilow Cancer Hospital Care Center - Guilford
      • Hartford, Connecticut, 미국, 06105
        • Smilow Cancer Hospital Care Center at Saint Francis
      • New Haven, Connecticut, 미국, 06520
        • Yale University
      • New Haven, Connecticut, 미국, 06510
        • Smilow Cancer Center/Yale-New Haven Hospital
      • North Haven, Connecticut, 미국, 06473
        • Yale-New Haven Hospital North Haven Medical Center
      • Orange, Connecticut, 미국, 06477
        • Smilow Cancer Hospital-Orange Care Center
      • Torrington, Connecticut, 미국, 06790
        • Smilow Cancer Hospital-Torrington Care Center
      • Trumbull, Connecticut, 미국, 06611
        • Smilow Cancer Hospital Care Center-Trumbull
      • Waterbury, Connecticut, 미국, 06708
        • Smilow Cancer Hospital-Waterbury Care Center
      • Waterford, Connecticut, 미국, 06385
        • Smilow Cancer Hospital Care Center - Waterford
    • Massachusetts
      • Boston, Massachusetts, 미국, 02215
        • Beth Israel Deaconess Medical Center
      • Boston, Massachusetts, 미국, 02215
        • Dana-Farber Cancer Institute
    • Michigan
      • Detroit, Michigan, 미국, 48201
        • Wayne State University/Karmanos Cancer Institute
    • New Jersey
      • New Brunswick, New Jersey, 미국, 08903
        • Rutgers Cancer Institute of New Jersey
    • Ohio
      • Columbus, Ohio, 미국, 43210
        • Ohio State University Comprehensive Cancer Center
    • Pennsylvania
      • Pittsburgh, Pennsylvania, 미국, 15232
        • UPMC Hillman Cancer Center
    • Virginia
      • Richmond, Virginia, 미국, 23298
        • VCU Massey Comprehensive Cancer Center

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

남성

설명

Inclusion Criteria:

  • Participants must have histologically or cytologically confirmed prostate cancer (code 10036910) with progressive disease at the time of study entry by either

    • Sequence of at least 2 rising PSA values at a minimum of 1-week intervals
    • Radiographic progression per RECIST1.1 for soft tissue and/or per PCWG3^2 for bone, with or without PSA progression
  • Patients must have metastatic disease by bone scan or other nodal or visceral lesions on computed tomography (CT) or magnetic resonance imaging (MRI) and a castrate level of testosterone (< 50 ng/dL) and evaluable for disease response by either

    • Baseline PSA >= 2.0 ng/mL OR
    • Measurable disease per RECIST 1.1
    • NOTE: Subjects must maintain a castrate state; if they have not had an orchiectomy, they must continue to receive luteinizing hormone-releasing hormone (LHRH) or gonadotropin-releasing hormone (GnRH) agonists or antagonists unless intolerant
  • At least 2 prior treatments for castration resistant prostate cancer as follows:

    • Past progression or intolerance to at least one secondary hormonal therapy (abiraterone, enzalutamide, galeterone, apalutamide, darolutamide, orteronel, seviteronel or equivalent)
    • Past progression or intolerance to taxane-based chemotherapy
  • Eastern Cooperative Oncology Group (ECOG) performance status =< 1 (Karnofsky >= 70%)

  • Leukocytes >= 3,000/mcL

  • Absolute neutrophil count >= 1,500/mcL

  • Hemoglobin >= 9 g/dL (transfusion permitted)

  • Platelets >= 150,000/mcL (without transfusion or growth factor in prior 28 days)

  • Total bilirubin =< 1.5 x institutional upper limit of normal, unless the subject has known or suspected Gilbert's syndrome

  • Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x institutional upper limit of normal or =< 5 x if presence of liver metastases

  • Creatinine clearance >= 40 mL/min/1.73 m^2

  • Prior treatment with mTOR inhibitors, cytostatic tyrosine kinase inhibitor (TKI), or biologic therapies allowed

  • Prior treatment with PARP inhibitors permitted

  • Patients with allergy or intolerance to docetaxel, grade 2 neuropathy are allowed on study, but if randomized to Arm A will receive carboplatin as a single agent (area under curve [AUC] 5) rather than docetaxel+carboplatin; they must be fit for carboplatin chemotherapy as determined by the treating investigator

  • Presence of a lesion (bone or soft tissue) amenable to image-guided percutaneous biopsy adequate for next generation sequencing (NGS), and planned to undergo core biopsy after trial registration but prior to cycle 1 day 1 of therapy; confirmation of adequacy of this biopsy material for NGS is NOT required for initiation of therapy; if elective biopsies are not being performed at the treating institution due to preparations or precautions related to coronavirus disease 2019 (COVID-19), this requirement can be waived on discussion with the trial principal investigator (PI)

  • The effects of M6620 (VX-970, berzosertib), carboplatin and docetaxel on the developing human fetus are unknown. For this reason and because DNA-damage response inhibitors and chemotherapeutic agents are known to be teratogenic, men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 6 months after completion of carboplatin and M6620 (VX-970, berzosertib) administration

  • Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

  • Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to planned cycle 1 day 1 of study treatment; patients on an oral anti-neoplastic such as an oral hormonal agent, PARP inhibitor or oral experimental agent should discontinue >= 14 days prior to planned cycle 1 day 1 of study treatment

  • Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > grade 1), except for grade 2 anorexia, alopecia, neuropathy, and fatigue, for which resolution is not required

  • Patients who are receiving any other investigational agents

  • Patients with known brain metastases or leptomeningeal disease should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events

  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to M6620 (VX-970, berzosertib) or carboplatin; (patients with allergy to docetaxel will be allowed on study, but docetaxel will be excluded from their treatment regimen)

  • Subjects receiving treatment with ototoxic or nephrotoxic medications that cannot be discontinued at least 7 days before first dose of carboplatin and for the duration of the study; inadvertent or short-term use on study will not cause a subject to be ineligible; if a short course of therapy with nephrotoxic or ototoxic medication is anticipated and required, carboplatin should be discontinued until 7 days after this course is completed; patients on continuous medications that are potentially nephrotoxic who have had no evidence of nephrotoxicity from these medications at study entry are allowed to continue those medicines on trial

    • M6620 (VX-970, berzosertib) is primarily metabolized by CYP3A4; therefore, concomitant administration with strong inhibitors of CYP3A4 (e.g., ketoconazole, itraconazole, clarithromycin, ritonavir, indinavir, nelfinavir and saquinavir) or inducers of CYP3A4 (e.g. rifampin, phenytoin, carbamazepine, phenobarbital, St. John's Wort) is prohibited; because the lists of these agents are constantly changing, it is important to regularly consult a frequently-updated medical reference for a list of drugs to avoid or minimize use of; Patient Drug Information Handout and Wallet Card should be provided to patients; as part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements

  • Pregnant and nursing women are excluded from this study because they do not develop prostate cancer

  • Human immunodeficiency (HIV)-positive participants with detectable viral load and/or CD4 count =< 300 are ineligible due to increased risk of lethal infections when treated with marrow-suppressive therapy; HIV-positive patients with undetectable viral loads and CD4 counts > 300, and not on interacting antiretroviral therapy may be eligible after discussing with the principal investigator

  • Prior treatment with platinum-containing regimen or ATR inhibitor for prostate cancer

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
활성 비교기: Arm A (docetaxel, carboplatin)

Patients receive docetaxel IV over 60 minutes and carboplatin IV over 30 minutes, or carboplatin alone on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients who have PSA progression or radiographic progression may crossover to Arm B.

Given IV

다른 이름들:
  • 폭발탄
  • 카르보플라트
  • 카보플라틴 헥살
  • 카르보플라티노
  • 카보플라티넘
  • 카르보신
  • 카보솔
  • 카보텍
  • CBDCA
  • 디스플라타
  • 에르카르
  • JM-8
  • 닐로린
  • 노보플라티넘
  • 파라플라틴
  • 파라플라틴 AQ
  • 플라틴와스
  • 리보카르보
  • JM8

Correlative studies

Given IV

다른 이름들:
  • 탁소테레
  • 도세캐드
  • RP56976
  • 탁소테레 주사 농축액
  • RP 56976
  • RP-56976
실험적: Arm B (carboplatin, berzosertib)

Patients receive carboplatin IV over 30 minutes on day 1 and berzosertib IV over 60-90 minutes on days 2 and 9. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.

Given IV

다른 이름들:
  • 폭발탄
  • 카르보플라트
  • 카보플라틴 헥살
  • 카르보플라티노
  • 카보플라티넘
  • 카르보신
  • 카보솔
  • 카보텍
  • CBDCA
  • 디스플라타
  • 에르카르
  • JM-8
  • 닐로린
  • 노보플라티넘
  • 파라플라틴
  • 파라플라틴 AQ
  • 플라틴와스
  • 리보카르보
  • JM8

Correlative studies

Given IV

다른 이름들:
  • 2-피라진아민, 3-(3-(4-((메틸아미노)메틸)페닐)-5-이속사졸릴)-5-(4-((1-메틸에틸)술포닐)페닐)-
  • 남 6620
  • M6620
  • VX 970
  • VX-970
  • VX970

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Overall Response Rate
기간: Radiologic measurements are performed every 3 cycles Up to 2 years. PSA measurements are performed every cycle up to 2 years

Defined by radiographic response by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 or prostate specific antigen [PSA] response (> 50% decline from baseline).

Radiologic measurements are performed every 3 cycles Up to 2 years. PSA measurements are performed every cycle up to 2 years

2차 결과 측정

결과 측정
측정값 설명
기간
Progression-free Survival (PFS)
기간: From the time of randomization up to 2 years

Assessed by Prostate Cancer Working Group (PCWG) 3 criteria. PFS to be estimated with the Kaplan Meier methodology. Median will be provided with 95% confidence interval.

From the time of randomization up to 2 years
Time to PSA Progression
기간: From the time of randomization up to 2 years

Assessed by PCWG2. PSA progression will be estimated with the Kaplan Meier methodology. Median will be provided with 95% confidence interval.

From the time of randomization up to 2 years
Radiographic Progression-free Survival (rPFS)
기간: From the time of randomization up to 2 years

Assessed by RECIST 1.1 for non-osseous disease and by PCWG3 for osseous disease. rPFS will be estimated with the Kaplan Meier methodology. Median will be provided with 95% confidence interval.

From the time of randomization up to 2 years
Incidence of Adverse Events
기간: Up to 2 years (from treatment initiation to 30 days after the last dose of study treatment)

Adverse events will be graded and analyzed using Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.

Up to 2 years (from treatment initiation to 30 days after the last dose of study treatment)

기타 결과 측정

결과 측정
측정값 설명
기간
Overall Survival (OS)
기간: From the time of randomization up to 2 years

OS will be estimated with the Kaplan Meier methodology.

From the time of randomization up to 2 years
Gene Mutation Frequencies
기간: At baseline

The frequency of homologous recombination (HR) deficiency detected from baseline tumor biopsy is summarized by arm at baseline.

At baseline

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 수석 연구원: Atish D Choudhury, Dana-Farber - Harvard Cancer Center LAO

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2019년 5월 29일

기본 완료 (실제)

2021년 8월 10일

연구 완료 (추정된)

2027년 4월 3일

연구 등록 날짜

최초 제출

2018년 5월 7일

QC 기준을 충족하는 최초 제출

2018년 5월 7일

처음 게시됨 (실제)

2018년 5월 8일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 13일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 11일

마지막으로 확인됨

2026년 10월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • NCI-2018-00790
  • UM1CA186709 (미국 NIH 보조금/계약)
  • NCI-2018-00790 (레지스트리 식별자: CTRP (Clinical Trial Reporting Program))
  • 10191 (기타 식별자: CTEP)
  • 10191 (기타 식별자: Dana-Farber - Harvard Cancer Center LAO)

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다